PDCD1 and rectal cancer: In light of our results, we believe that the use of anti-TIGIT mAbs should be developed for colon- and rectal-cancer patients, not in combination with anti-PD-1 or -PD-L1 antibodies, but rather, in combination with other ICis according to IC expression levels.